# Spironolactone Therapy in Chronic Stable Right HF Trial

> **NCT03344159** · PHASE4 · COMPLETED · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 15 (actual)

## Conditions studied

- Chronic Right-Sided Heart Failure
- Pulmonary Arterial Hypertension
- Pulmonary Hypertension, Primary, 2
- Pulmonary Hypertension, Primary, 3
- Pulmonary Hypertension, Primary, 4
- Cardiomyopathy Right Ventricular

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Placebo
- **RADIATION:** PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82
- **DIAGNOSTIC_TEST:** Cardiac MRI (Gadolinium enhanced)

## Key facts

- **NCT ID:** NCT03344159
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-01
- **Primary completion:** 2022-08-30
- **Final completion:** 2024-05-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344159, "Spironolactone Therapy in Chronic Stable Right HF Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03344159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*